1-20 of 98
Gordon B. Mills
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study

Austin R. Pantel, Sarah B. Gitto, Mehran Makvandi, Hyoung Kim, Sergey Medvedv, Joanna K. Weeks, Drew A. Torigian, Chia-Ju Hsieh, Benjamin Ferman, Nawar A. Latif, Janos L. Tanyi, Lainie P. Martin, Shannon M. Lanzo, Fang Liu, Quy Cao, Gordon B. Mills, Robert K. Doot, David A. Mankoff, Robert H. Mach, Lilie L. Lin, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1515–1527.
https://doi.org/10.1158/1078-0432.CCR-22-1602
Published: 14 April 2023
View article titled, [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
Open the PDF for [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study in another window
Includes: Supplementary data
Journal Articles

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkilä, Zena Wilson, Adina Hughes, Paul W.G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquin Arribas, Javier Cortés, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmaña, Mark J. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4536–4550.
https://doi.org/10.1158/1078-0432.CCR-22-0568
Published: 14 October 2022
View article titled, Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Open the PDF for Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection

Xiuning Le, Frederico O. Gleber-Netto, M. Laura Rubin, Yun Qing, Robyn Du, Merrill Kies, George Blumenschein, Jr, Charles Lu, Faye M. Johnson, Diana Bell, Jeff Lewis, Jiexin Zhang, Lei Feng, Kaye Wilson, Kathrina Marcelo-Lewis, Jing Wang, Lawrence Ginsberg, Maura Gillison, J. Jack Lee, Funda Meric-Berstam, Gordon B. Mills, William N. William, Jr, Jeffrey N. Myers, Curtis R. Pickering
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2796–2806.
https://doi.org/10.1158/1078-0432.CCR-21-3239
Published: 01 July 2022
View article titled, Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection
Open the PDF for Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas

Shiyou Wei, Delong Yin, Shengnan Yu, Xiang Lin, Milan R. Savani, Kuang Du, Yin Ku, Di Wu, Shasha Li, Hao Liu, Meng Tian, Yaohui Chen, Michelle Bowie, Seethalakshmi Hariharan, Matthew Waitkus, Stephen T. Keir, Eric T. Sugarman, Rebecca A. Deek, Marilyne Labrie, Mustafa Khasraw, Yiling Lu, Gordon B. Mills, Meenhard Herlyn, Kongming Wu, Lunxu Liu, Zhi Wei, Keith T. Flaherty, Kalil Abdullah, Gao Zhang, David M. Ashley
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2180–2195.
https://doi.org/10.1158/1078-0432.CCR-21-0833
Published: 13 May 2022
View article titled, Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Open the PDF for Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas in another window
Includes: Supplementary data
Journal Articles

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Shannon N. Westin, Marilyne Labrie, Jennifer K. Litton, Aurora Blucher, Yong Fang, Christopher P. Vellano, Joseph R. Marszalek, Ningping Feng, XiaoYan Ma, Allison Creason, Bryan Fellman, Ying Yuan, Sanghoon Lee, Tae-Beom Kim, Jinsong Liu, Anca Chelariu-Raicu, Tsun Hsuan Chen, Nashwa Kabil, Pamela T. Soliman, Michael Frumovitz, Katheleen M. Schmeler, Amir Jazaeri, Karen H. Lu, Rashmi Murthy, Larissa A. Meyer, Charlotte C. Sun, Anil K. Sood, Robert L. Coleman, Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6354–6365.
https://doi.org/10.1158/1078-0432.CCR-21-1656
Published: 01 December 2021
View article titled, Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
Open the PDF for Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer

Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey V. Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4587–4598.
https://doi.org/10.1158/1078-0432.CCR-21-0180
Published: 15 August 2021
View article titled, Clinical and Functional Characterization of Atypical <em>KRAS</em>/<em>NRAS</em> Mutations in Metastatic Colorectal Cancer
Open the PDF for Clinical and Functional Characterization of Atypical <em>KRAS</em>/<em>NRAS</em> Mutations in Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer

Argun Akcakanat, Xiaofeng Zheng, Christian X. Cruz Pico, Tae-Beom Kim, Ken Chen, Anil Korkut, Aysegul Sahin, Vijaykumar Holla, Emily Tarco, Gopal Singh, Senthil Damodaran, Gordon B. Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3243–3252.
https://doi.org/10.1158/1078-0432.CCR-20-4048
Published: 01 June 2021
View article titled, Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Open the PDF for Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PO-094: Glutaminase inhibition increases ionizing radiation induced oxidative stress and DNA damage in head and neck squamous cell carcinoma models

Christina A. Wicker, Brian G. Hunt, Sarah Palackdharry, William R. Elaban, Trisha M. Wise-Draper, Gordon B. Mills, Susan E. Waltz, Vinita Takiar
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8_Supplement): PO-094.
https://doi.org/10.1158/1557-3265.RADSCI21-PO-094
Published: 15 April 2021
View article titled, Abstract PO-094: Glutaminase inhibition increases ionizing radiation induced oxidative stress and DNA damage in head and neck squamous cell carcinoma models
Journal Articles

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

Charles Marusak, Varsha Thakur, Yuan Li, Juliano T. Freitas, Patrick M. Zmina, Vijay S. Thakur, Mayland Chang, Ming Gao, Jiufeng Tan, Min Xiao, Yiling Lu, Gordon B. Mills, Keith Flaherty, Dennie T. Frederick, Benchun Miao, Ryan J. Sullivan, Tabea Moll, Genevieve M. Boland, Meenhard Herlyn, Gao Zhang, Barbara Bedogni
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 6039–6050.
https://doi.org/10.1158/1078-0432.CCR-19-2773
Published: 13 November 2020
View article titled, Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Open the PDF for Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma in another window
Includes: Supplementary data
Journal Articles

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H. Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S. Hirst, Alan Barnicle, Elza C. de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B. Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C. Turner, Cristina Saura, Barry R. Davies, Mafalda Oliveira, Violeta Serra
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3720–3731.
https://doi.org/10.1158/1078-0432.CCR-19-3324
Published: 15 July 2020
View article titled, Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Open the PDF for Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts in another window
Includes: Supplementary data
Journal Articles

Abstract PR03: Single-cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor

Nicholas D. Kendsersky, Hongli Ma, Yong Fang, Lydia G. Campbell, Jenny Eng, Sanghoon Lee, Koei Chin, Shannon N. Westin, Gordon B. Mills, Marilyne Labrie
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): PR03.
https://doi.org/10.1158/1557-3265.OVCA19-PR03
Published: 01 July 2020
View article titled, Abstract PR03: Single-cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor
Journal Articles

Abstract NT-098: WINDOW OF OPPORTUNITY TRIAL: ASSESSING THE ADAPTIVE RESPONSE OF HGSOC TO PARPI FOR INFORMED COMBINATION THERAPIES

Marilyne Labrie, Tae-Beom Kim, Zhenlin Ju, Sanghoon Lee, Yiling Lu, Ken Chen, Gordon B. Mills, Shannon N. Westin
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): NT-098.
https://doi.org/10.1158/1557-3265.OVCASYMP18-NT-098
Published: 15 November 2019
View article titled, Abstract NT-098: WINDOW OF OPPORTUNITY TRIAL: ASSESSING THE ADAPTIVE RESPONSE OF HGSOC TO PARPI FOR INFORMED COMBINATION THERAPIES
Journal Articles

COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms

Antje Lindemann, Ameeta A. Patel, Natalie L. Silver, Lin Tang, Zhiyi Liu, Li Wang, Noriaki Tanaka, Xiayu Rao, Hideaki Takahashi, Nakachi K. Maduka, Mei Zhao, Tseng-Cheng Chen, WeiWei Liu, Meng Gao, Jing Wang, Steven J. Frank, Walter N. Hittelman, Gordon B. Mills, Jeffrey N. Myers, Abdullah A. Osman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (18): 5650–5662.
https://doi.org/10.1158/1078-0432.CCR-19-0096
Published: 13 September 2019
View article titled, COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms
Open the PDF for COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms in another window
Includes: Multimedia, Supplementary data
Journal Articles

Advancing Drug Development in Gynecologic Malignancies

Julia A. Beaver, Robert L. Coleman, Rebecca C. Arend, Deborah K. Armstrong, Sanjeeve Bala, Gordon B. Mills, Anil K. Sood, Thomas J. Herzog
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 4874–4880.
https://doi.org/10.1158/1078-0432.CCR-19-0619
Published: 15 August 2019
View article titled, Advancing Drug Development in Gynecologic Malignancies
Open the PDF for Advancing Drug Development in Gynecologic Malignancies in another window
Journal Articles

PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma

Frederik Holst, Henrica M.J. Werner, Siv Mjøs, Erling A. Hoivik, Kanthida Kusonmano, Elisabeth Wik, Anna Berg, Even Birkeland, William J. Gibson, Mari K. Halle, Jone Trovik, Andrew D. Cherniack, Karl-Henning Kalland, Gordon B. Mills, Christian F. Singer, Camilla Krakstad, Rameen Beroukhim, Helga B. Salvesen
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 334–345.
https://doi.org/10.1158/1078-0432.CCR-18-0452
Published: 03 January 2019
View article titled, <em>PIK3CA</em> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma
Open the PDF for <em>PIK3CA</em> Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells

Fiona Simpkins, Kibeom Jang, Hyunho Yoon, Karina E. Hew, Minsoon Kim, Diana J. Azzam, Jun Sun, Dekuang Zhao, Tan A. Ince, Wenbin Liu, Wei Guo, Zhi Wei, Gao Zhang, Gordon B. Mills, Joyce M. Slingerland
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (19): 4874–4886.
https://doi.org/10.1158/1078-0432.CCR-17-3697
Published: 01 October 2018
View article titled, Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Open the PDF for Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells in another window
Includes: Supplementary data
Journal Articles

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma

Gao Zhang, Lawrence W. Wu, Ilgen Mender, Michal Barzily-Rokni, Marc R. Hammond, Omotayo Ope, Chaoran Cheng, Themistoklis Vasilopoulos, Sergio Randell, Norah Sadek, Aurelie Beroard, Min Xiao, Tian Tian, Jiufeng Tan, Umar Saeed, Eric Sugarman, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Sengottuvelan Murugan, Rajasekharan Somasundaram, Bradley Garman, Bradley Wubbenhorst, Jonathan Woo, Xiangfan Yin, Qin Liu, Dennie T. Frederick, Benchun Miao, Wei Xu, Giorgos C. Karakousis, Xiaowei Xu, Lynn M. Schuchter, Tara C. Mitchell, Lawrence N. Kwong, Ravi K. Amaravadi, Yiling Lu, Genevieve M. Boland, Zhi Wei, Katherine Nathanson, Utz Herbig, Gordon B. Mills, Keith T. Flaherty, Meenhard Herlyn, Jerry W. Shay
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (19): 4771–4784.
https://doi.org/10.1158/1078-0432.CCR-17-2773
Published: 01 October 2018
View article titled, Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Open the PDF for Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract IA13: Systems approach to drug development

Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): IA13.
https://doi.org/10.1158/1557-3265.OVCA17-IA13
Published: 01 August 2018
View article titled, Abstract IA13: Systems approach to drug development
Journal Articles

Abstract A09: Rational combinational therapy with PARP and BRD4 inhibitor in ovarian cancer

Chaoyang Sun, Jun Yin, Yong Fang, Gordon B. Mills
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): A09.
https://doi.org/10.1158/1557-3265.OVCA17-A09
Published: 01 August 2018
View article titled, Abstract A09: Rational combinational therapy with PARP and BRD4 inhibitor in ovarian cancer
Journal Articles

Abstract B44: Early loss of monoubiquitylation of H2B alters key metabolic and immune signaling pathways promoting the progression of high-grade serous ovarian cancer

Jagmohan Hooda, Marian Novak, Emily MacDuffie, Melissa Song, Jenny Lester, Vinita Parkash, Gordon B. Mills, Beth Y. Karlan, Moshe Oren, Ronny Drapkin
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): B44.
https://doi.org/10.1158/1557-3265.OVCA17-B44
Published: 01 August 2018
View article titled, Abstract B44: Early loss of monoubiquitylation of H2B alters key metabolic and immune signaling pathways promoting the progression of high-grade serous ovarian cancer